• LAST PRICE
    2.2400
  • TODAY'S CHANGE (%)
    Trending Down-0.2500 (-10.0402%)
  • Bid / Lots
    2.2000/ 23
  • Ask / Lots
    2.4700/ 10
  • Open / Previous Close
    2.3900 / 2.4900
  • Day Range
    Low 2.0300
    High 2.4200
  • 52 Week Range
    Low 1.5600
    High 4.0800
  • Volume
    57,019
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.49
TimeVolumeINDP
09:32 ET36922.4
09:34 ET1002.39
09:36 ET2002.42
09:39 ET8182.42
09:41 ET3482.4
09:43 ET7732.39
09:48 ET108062.23
09:50 ET90162.04
09:52 ET3002.1301
09:57 ET8002.2703
09:59 ET2002.28
10:01 ET6462.2
10:03 ET2002.187
10:08 ET5002.27
10:12 ET4902.12
10:19 ET5002.2502
10:21 ET1002.28
10:48 ET6342.25
11:00 ET1002.29
11:11 ET8572.2401
11:26 ET42432.2704
11:51 ET50002.315
12:07 ET5002.3613
12:27 ET49812.26
12:48 ET5002.3028
01:12 ET1002.3693
01:53 ET10002.295
01:57 ET1002.28
02:08 ET3592.26
02:20 ET1402.27
02:40 ET5332.26
02:42 ET4502.22
02:45 ET3002.22
03:02 ET1002.3
03:21 ET1002.3
03:36 ET6102.2705
03:38 ET5502.28
03:59 ET10062.24
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesINDP
Indaptus Therapeutics Inc
21.3M
-1.2x
---
United StatesGLTO
Galecto Inc
21.1M
-0.5x
---
United StatesITRM
Iterum Therapeutics PLC
21.4M
-0.6x
---
United StatesNRBO
NeuroBo Pharmaceuticals Inc
21.1M
-0.6x
---
United StatesIMUC
Eom Pharmaceutical Holdings Inc
20.7M
-3.5x
---
United StatesCNTX
Context Therapeutics Inc
22.1M
-0.9x
---
As of 2024-03-28

Company Information

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Contact Information

Headquarters
3 Columbus Circle, 15Th FloorNEW YORK, NY, United States 10019
Phone
646-427-2727
Fax
---

Executives

Independent Non-Executive Chairman of the Board
Roger Pomerantz
Chief Executive Officer, Director
Jeffrey Meckler
Chief Financial Officer, Treasurer, Secretary
Nir Sassi
Chief Operating Officer
Walt Linscott
Chief Scientific Officer, Director
Michael Newman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$21.3M
Revenue (TTM)
$0.00
Shares Outstanding
8.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-1.84
Book Value
$1.44
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.